Responding to a potentially disruptive technology: How big pharma embraced biotechnology

Julian Birkinshaw, Ivanka Visnjic, Simon Best

Producció científica: Article en revista indexadaArticleAvaluat per experts

15 Cites (Scopus)


How do incumbent firms respond over time to a potentially disruptive technology? This article documents the strategies of 12 large pharmaceutical firms over 25 years as they addressed the opportunity/threat of biotechnology. All showed awareness of biotechnology’s potential, but their response profiles varied dramatically in terms of timing (early/late) and focus (external/internal). Late movers mostly made large acquisitions to “catch up,” but early movers maintained their lead in terms of biotechnology-based drug sales and profitability, and those with a more “open” response profile performed better. This response involves a three-step process: building awareness (sensing), building capability (responding), and building commitment (scaling).

Idioma originalAnglès
Pàgines (de-a)74-100
Nombre de pàgines27
RevistaCalifornia Management Review
Estat de la publicacióPublicada - 1 d’ag. 2018
Publicat externament

Com citar-ho